To include your compound in the COVID-19 Resource Center, submit it here.

Ignyta's entrectinib leads to durable responses in NSCLC population

Ignyta Inc. (NASDAQ:RXDX) climbed $1.90 (13%) to $16.25 on Wednesday after reporting interim data from the Phase II STARTRK-2 basket study of entrectinib (RXDX-101) to treat non-small

Read the full 274 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE